The Australian share market has finished down 0.4 per cent in large part because of a failed heart attack drug that CSL spent nearly $1 billion developing.
The Australian share market has finished down 0.4 per cent in large part because of a failed heart attack drug that CSL spent nearly $1 billion developing.